Press Releases

Date Title and Summary Additional Formats
Toggle Summary TYMLOS Label and Business Update
TYMLOS® label: significant update to the Mechanism of Action (MOA) section Label change aligns with strategic focus on postmenopausal women at high risk of fracture Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team Added ~3,000 new TYMLOS patients throughout
View HTML
Toggle Summary The NASDAQ OMX Group, Inc. Today Announced That Radius Health Will be Added to Its Biotechnology Index Effective Before Market Open on Monday, December 22, 2014
As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014. WALTHAM, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc.
View HTML
Toggle Summary The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis
-- Multi-center, multi-national, double-blind, placebo-controlled trial in which postmenopausal women were randomized to receive 24-weeks of treatment with either daily subcutaneous injections of placebo, the investigational drug abaloparatide 20, 40 or 80-μg, or teriparatide 20-μg.
View HTML
Toggle Summary Sean Murphy joins Radius Health Board of Directors
WALTHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,
View HTML
Toggle Summary Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis View HTML
Toggle Summary Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis Cambridge, Mass., December 20, 2012 – Radius Health , Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership
View HTML
Toggle Summary Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis View HTML
Toggle Summary Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy CAMBRIDGE, MA--(Marketwire - Dec 5, 2011) - C. Richard Lyttle retires as President and CEO and will serve as interim CSO Kurt Graves
View HTML
Toggle Summary Radius to Host Investor Day on June 8, 2018
Advancing Treatment Care for Osteoporosis
View HTML
Toggle Summary Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection CAMBRIDGE, MA--(Marketwire - Jan 7, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, is
View HTML